Altimmune (MEX:ALT1) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ALT1 Altimmune Inc MEX:ALT1
41 GF Score
Price MXN56.00
GF Value MXN5.37
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Altimmune Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Altimmune's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was MXN4.79 Mil. Altimmune's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was MXN624.62 Mil. Altimmune's annualized EBITDA for the quarter that ended in Jun. 2026 was MXN-1,510.25 Mil. Altimmune's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -0.42.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Altimmune's Debt-to-EBITDA or its related term are showing as below:

MEX:ALT1' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.41   Med: -0.02   Max: -0.01
Current: -0.41

During the past 13 years, the highest Debt-to-EBITDA Ratio of Altimmune was -0.01. The lowest was -0.41. And the median was -0.02.

MEX:ALT1's Debt-to-EBITDA is ranked worse than
100% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs MEX:ALT1: -0.41

Altimmune  (MEX:ALT1) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Altimmune Debt-to-EBITDA Related Terms

Altimmune Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Altimmune's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altimmune Debt-to-EBITDA Chart

Altimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Altimmune Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MEX:ALT1 vs ARVN, AUTL, EIKN: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Altimmune's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Altimmune Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Altimmune's Debt-to-EBITDA falls into.


MEX:ALT1
41GF Score
Altimmune Inc MEX:ALT1
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altimmune Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Altimmune's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.602752 + 637.049644) / -1670.93183475
=-0.38

Altimmune's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.7878075 + 624.6166675) / -1510.2508693636
=-0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Altimmune (MEX:ALT1) Overvalued in 2026?

Based on GuruFocus' analysis, Altimmune stock appears to be overvalued. The current stock price of MXN56.00 is trading 942.8% above its estimated GF Value™ of MXN5.37. GuruFocus considers Altimmune to be Significantly Overvalued.

Key valuation signals for MEX:ALT1:

  • Debt-to-EBITDA:
  • GF Value™: MXN5.37 vs. price of MXN56.00 (942.8% above fair value)
  • GF Score™: 41/100 with 2 warning signs

No single metric tells the full story. See the MEX:ALT1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Altimmune Business Description

Other Exchanges ALT:USA0A4C:UK3G0:Germany
Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
41GF Score

Get the complete analysis for MEX:ALT1

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN56.00
Price
MXN5.37
GF Value